The Endovascular Treatment Devices Market is becoming an increasingly important segment of the global medical device industry as healthcare providers seek safer, less invasive, and more efficient solutions for treating vascular disorders. Endovascular procedures enable physicians to access blood vessels through small entry points and use specialized catheters, stents, grafts, balloons, and thrombectomy systems to diagnose and treat disease. The approach has gained substantial acceptance because it can reduce surgical trauma and support faster recovery in appropriately selected patients.
According to the provided market outlook, the global endovascular treatment devices market was valued at US$3.7 billion in 2025 and is expected to reach approximately US$9.7 billion by 2036, expanding at a CAGR of 9.2% between 2026 and 2036. Rising vascular disease prevalence, improvements in medical technology, and increasing adoption of minimally invasive procedures are expected to remain the primary forces behind this expansion.
Increasing Vascular Disease Burden Creates Strong Demand
The growing incidence of cardiovascular and vascular disorders is one of the fundamental factors supporting market growth. Peripheral artery disease, aortic aneurysms, thrombosis, and other vascular conditions affect millions of people globally, with risk increasing as populations age.
Several lifestyle and metabolic factors are contributing to the disease burden. Diabetes, hypertension, obesity, smoking, poor dietary habits, and physical inactivity can increase the risk of vascular complications. The expansion of these risk factors in both developed and emerging economies is creating a larger patient population requiring diagnosis and treatment.
As physicians identify vascular disorders earlier and patients seek less invasive treatment options, demand for endovascular technologies is increasing. Devices that restore blood flow, reinforce weakened arteries, open narrowed vessels, or remove blood clots are becoming important components of modern vascular care.
The preference for minimally invasive interventions is particularly significant because conventional open surgery can require larger incisions and longer recovery periods. Endovascular procedures may reduce hospital stays and postoperative recovery time for suitable patients, supporting their broader adoption.
Technological Development Accelerates Industry Growth
Innovation is transforming the capabilities of endovascular treatment devices. Manufacturers are investing heavily in the development of products that offer improved flexibility, precision, deliverability, durability, and clinical performance.
Stents and stent-grafts are among the most important technologies in this field. Modern devices are increasingly designed to navigate challenging vascular anatomy and provide stable support within blood vessels. Drug-eluting stents add another dimension by delivering medication locally to the treatment area.
Balloon catheter technologies are also evolving. Improved balloon designs can provide greater control during vessel dilation, while advanced catheter systems are allowing physicians to reach increasingly difficult anatomical locations.
Thrombectomy devices represent another rapidly developing area. These systems are designed to remove blood clots through catheter-based techniques, offering minimally invasive options for selected patients with acute vascular obstruction.
The integration of sophisticated imaging and navigation technologies is also improving procedural accuracy. Advanced imaging can help physicians visualize blood vessels and position devices more precisely, while robotics and artificial intelligence may eventually enhance decision-making and procedural control.
EVAR Devices Maintain a Leading Position
The Percutaneous Endovascular Aneurysm Repair (EVAR) devices segment represented approximately 28.7% of the market in 2025, making it a leading product category.
EVAR is used to treat certain aortic aneurysms by placing a stent-graft inside the affected section of the vessel. The graft helps reinforce the weakened arterial wall and redirect blood flow, reducing pressure on the aneurysm.
The demand for EVAR devices is being supported by an aging population and the increasing prevalence of risk factors associated with aortic aneurysms. Improvements in graft design and delivery systems are further strengthening the segment.
One important area of development is fenestrated EVAR. Fenestrated systems are designed for anatomically complex cases in which important branch vessels must remain accessible. Such technologies can potentially expand endovascular treatment to patients with more challenging aneurysm anatomy.
Manufacturers are also developing customizable grafts and more sophisticated delivery systems. These developments can help physicians achieve better anatomical fit and procedural control.
Diverse Procedure Types Expand Market Opportunities
The endovascular treatment devices industry includes several major procedure categories. These include balloon angioplasty, angioplasty with stent placement, drug-eluting stent procedures, thrombolysis/thrombectomy, renal artery angioplasty and stenting, and other interventions.
Balloon angioplasty remains an established method for widening narrowed blood vessels. Stent placement can provide additional structural support and help maintain vessel patency. The continued evolution of stent technology is creating opportunities for devices with improved mechanical characteristics and drug-delivery capabilities.
Thrombectomy and thrombolysis are also important growth areas because blood-clot-related vascular conditions require rapid and effective intervention. New catheter technologies are designed to provide physicians with greater control during clot removal.
Renal artery angioplasty and stenting provide another specialized application, while continued advances in catheter-based technologies may broaden the range of vascular disorders that can be treated without open surgery.
North America Remains a Major Regional Market
North America held the largest share of the global market in 2025, accounting for approximately 38.7%.
The region benefits from advanced medical infrastructure, widespread availability of specialized healthcare services, established reimbursement systems, and strong adoption of innovative medical technologies. The presence of leading device manufacturers and research institutions further strengthens the regional ecosystem.
Healthcare professionals in the United States and Canada have significant experience with minimally invasive vascular procedures. Patient awareness of treatment options and the potential benefits of shorter recovery periods also contributes to adoption.
Europe represents another mature market, supported by sophisticated healthcare systems and continued investment in medical technology. Meanwhile, Asia Pacific offers significant long-term potential because of its large population, increasing healthcare expenditure, expanding hospital infrastructure, and rising prevalence of cardiovascular disease.
Emerging markets across Latin America and the Middle East & Africa could similarly provide opportunities as specialized healthcare capacity develops.
Competitive Landscape and Industry Innovation
The market features several prominent medical technology companies, including Medtronic, Boston Scientific, Terumo, Abbott Laboratories, Cardinal Health, W. L. Gore & Associates, Penumbra, Cook, Cordis, Endologix, Endospan, and other players.
Competition is focused on innovation, clinical performance, regulatory approvals, product portfolios, and geographic expansion. Companies are increasingly seeking to differentiate their products through improved deliverability, precision, anatomical adaptability, and procedural efficiency.
The pace of development remained strong in 2025. Jupiter Endovascular announced FDA 510(k) clearance for its Vertex catheter for insertion of endovascular devices. Terumo Aortic announced enrollment of the first patient in its Fenestrated TREO pivotal U.S. IDE study. Medtronic also received FDA labeling approval for its Endurant stent graft system involving ruptured abdominal aortic aneurysm clinical evidence.
Such developments demonstrate how manufacturers are continuing to expand treatment options and address unmet needs in vascular care.
Barriers That Could Limit Market Expansion
Despite its positive outlook, the market faces several challenges. Advanced endovascular devices can be expensive, and the overall cost of procedures may limit adoption in healthcare systems with constrained budgets.
Reimbursement is another important consideration. Differences in coverage policies and healthcare financing across countries can affect the accessibility of advanced vascular interventions.
Regulatory requirements can also increase the time and expense associated with developing and commercializing new devices. In addition, complex endovascular procedures require trained specialists, and shortages of experienced interventional professionals can restrict adoption in certain regions.
Addressing these barriers will require investment in medical education, infrastructure, reimbursement frameworks, and cost-effective technologies.
Emerging Opportunities in Global Vascular Care
The long-term opportunity for endovascular device manufacturers extends beyond established markets. Developing countries are increasing investments in hospitals, diagnostic services, specialist training, and advanced medical equipment.
Greater awareness of vascular diseases is also encouraging earlier diagnosis and treatment. As healthcare providers become more familiar with minimally invasive techniques, demand for modern vascular devices could increase significantly.
The integration of artificial intelligence, advanced imaging, robotics, and personalized device design could further change the industry. These technologies may help physicians perform complex interventions with greater precision while potentially expanding treatment options for difficult cases.
Manufacturers that can combine clinical effectiveness with affordability and ease of use may gain a competitive advantage, particularly in emerging healthcare markets.
Outlook Through 2036
The endovascular treatment devices industry is positioned for sustained growth during the coming decade. The projected increase from US$3.7 billion in 2025 to US$9.7 billion in 2036 demonstrates the substantial opportunity created by changing patient demographics, increasing disease prevalence, and technological innovation.
EVAR devices are expected to remain an important segment, while thrombectomy systems, advanced stents, balloon technologies, and other catheter-based products can contribute to future expansion. Regional diversification will also become increasingly important as manufacturers seek growth beyond mature healthcare markets.
Ultimately, the future of the market will depend on the industry’s ability to improve clinical outcomes, reduce procedural complexity, expand specialist capabilities, and make advanced vascular technologies more accessible.
